A major bone of contention in recent years has been the prices charged for AIDS drugs in the developing world by Western pharmaceutical giants such as Merck and Glaxo-SmithKline. Several makers of AIDS drugs, such as Merck, have now agreed to provide AIDS drugs in developing nations such as South Africa at a price that is roughly equivalent to the manufacturing costs. What potential hurdles do you see with this new pricing scheme?